Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.

Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.

Abstract: Provided herein are, inter alia, methods, compositions and kits for HCV antigen and vaccine design. Preferred methods include measuring neutralization of HCV pseudoparticles (HCVpp) by antibodies specific for an HCV in the biological sample, generating a neutralizations profile of each biological sample; deconvoluting the HCV-specific neutralizing antibodies by generating reference antibody neutralization profiles; correlating the reference antibody neutralization profiles to the biological sample's neutralization profile; and, identifying the HCV neutralizing antibodies.

Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.

Abstract: A continuously variable transmission includes two planetary gear sets having two planetary outputs and a planetary output shaft with a first drive gear. A variator drives a ring gear of the second planetary gear set, and a transmission input shaft is driven by the engine, which also drives the variator and the planetary input. Forward and reverse output systems are connected to the planetary output shaft and a transmission output shaft. A first clutch connects the first planetary output to the first drive gear, and a second clutch connects the second planetary output to the first drive gear. A third clutch connects the second planetary output to a second drive gear of the planetary output shaft, with the second drive gear being connected to the forward output system.

Abstract: A continuously variable transmission includes two planetary gear sets having two planetary outputs and a planetary output shaft with a first drive gear. A variator drives a ring gear of the second planetary gear set, and a transmission input shaft is driven by the engine, which also drives the variator and the planetary input. Forward and reverse output systems are connected to the planetary output shaft and a transmission output shaft. A first clutch connects the first planetary output to the first drive gear, and a second clutch connects the second planetary output to the first drive gear. A third clutch connects the second planetary output to a second drive gear of the planetary output shaft, with the second drive gear being connected to the forward output system.